Patent application number | Description | Published |
20080243015 | Visual Indicating Device for Bad Breath - The invention provides a breath testing device which includes a visual indicating agent which changes color in the presence of an odor associated with bad breath, such as sulfur and ammonia odors. An example of the visual indicating agent is 4,4′-bis(dimethylamino)-benzhydrol (Michler's hydrol or BDMB) and related dyes having a similar chemical structure. The indicating agent is applied to a substrate which is then inserted into a tube or straw, or which covers one end of a straw. When a user with bad breath blows into the tube or straw, the indicating agent will change color. The breath testing devices provide a quick and affordable means for a user to test their breath, and they may be packaged in discreet, pocket-sized dispensers which can be carried in a pocket or purse. | 10-02-2008 |
20090112538 | VIRTUAL REALITY SIMULATIONS FOR HEALTH CARE CUSTOMER MANAGEMENT - Embodiments of the invention provide virtual reality tools and simulations used for improved health care customer management. The virtual reality tools may be used by a product manufacturer or seller to assist in relationship management with health care partners including identifying improved solutions for a variety of problems, strengthening infection prevention processes and systems, improving order and flow in the operating room and other care-delivery environments, identifying benefits from new products, providing techniques for evaluating new health care systems and processes, etc. | 04-30-2009 |
20090157023 | Urine Volume Hydration Test Devices - In accordance with one embodiment of the present disclosure, a method for quantitatively or semi-quantitatively determining the volume of a test sample of urine is provided. The method includes contacting the test sample with a fluidic medium of a lateral flow device having a volume indicator disposed thereon and determining the volume of urine in the test sample based on the distance traveled by the volume indicator along the fluidic medium, the distance traveled by the volume indicator corresponding to the volume of urine in the test sample. | 06-18-2009 |
20090191647 | Antibody Pair Screening Methods - The invention provides methods for identifying antibody preparations that can form a pair of antibodies that optimally detect a target antigen, for example, in a sandwich immunoassay. These methods provide high affinity and epitope-specific antibodies. | 07-30-2009 |
20130261486 | Visual Indicating Device for Bad Breath - The invention provides a breath testing device which includes a visual indicating agent which changes color in the presence of an odor associated with bad breath, such as sulfur and ammonia odors. An example of the visual indicating agent is 4,4′-bis(dimethylamino)-benzhydrol (Michler's hydrol or BDMB) and related dyes having a similar chemical structure. The indicating agent is applied to a substrate which is then inserted into a tube or straw, or which covers one end of a straw. When a user with bad breath blows into the tube or straw, the indicating agent will change color. The breath testing devices provide a quick and affordable means for a user to test their breath, and they may be packaged in discreet, pocket-sized dispensers which can be carried in a pocket or purse. | 10-03-2013 |
20140087417 | Personal Care Products with Visual Indicator of Vaginitis - There is provided a personal care product having a body side liner, a baffle and an indicator strip with two ends. The indicator has an amine sensitive dye near at least one end. The indicator extends from the target area just below the liner to just above the baffle such that the dye deposit is visible to an unaided eye. The dye changes color in the presence of amines which are characteristic of infection, thus alerting the user to the possibility of infection. Such an indicator placed in a feminine hygiene pad, for example, may be useful in the diagnosis of vaginitis. | 03-27-2014 |
Patent application number | Description | Published |
20090118284 | Novel compounds that are ERK inhibitors - Disclosed are the ERK inhibitors of formula 1.0: | 05-07-2009 |
20110038876 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS - Disclosed are the ERK inhibitors of formula 1.0: [Formula (1.0)] and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0. | 02-17-2011 |
20130096084 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS - The present invention provides a compound of the Formula I: (Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same. | 04-18-2013 |
20130237518 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS - Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring) cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1). | 09-12-2013 |
20140206681 | BTK INHIBITORS - The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I | 07-24-2014 |
20140221333 | BTK INHIBITORS - Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders. | 08-07-2014 |
20150353570 | BTK INHIBITORS - The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders. | 12-10-2015 |